Skip to main content
SpringerLink
Log in

Antimykotika

  • Chapter
Arzneiverordnungs-Report 2003

  • 110 Accesses

Zusammenfassung

Pilzinfektionen werden klinisch-diagnostisch und therapeutisch nach ihrer Lokalisation und der Art der Erreger unterschieden. Am häufigsten sind oberflächliche Mykosen der Haut und Hautanhangsorgane sowie der Schleimhäute. Organmykosen sind in unseren Breiten deutlich seltener, haben aber bei Patienten mit erworbener Immunschwäche (AIDS) erhebliche Bedeutung und sind auch im Rahmen einer immunsuppressiven Therapie zu beachten. Für Risikopatienten kann auch die kommensale intestinale Mykoflora eine potentielle Gefahrenquelle sein (Blaschke-Hellmessen et al. 1996, Akpan und Morgan 2002). Ohne therapeutische Konsequenz ist sie jedoch — wie auch die übrige standorttypische Mikroflora — bei immunkompetenten Patienten. So läßt sich weder ein Zusammenhang zwischen einer Candidabesiedlung im Darm und Störungen wie Blähungen, Verdauungsbeschwerden, Roemheld-Syndrom, Herzbeschwerden, körperliche Schwäche, Ermüdbarkeit, Kopfschmerzen, Gelenkschmerzen, depressive Verstimmung etc. (sog. candidiasis hypersensitivity syndrome bzw. Mykophobie) wissenschaftlich belegen, noch ist eine Eradikation der Hefepilze notwendig und möglich (Lacour et al. 2002).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abeck D., Gruseck E., Körting H.C., Ring J. (1996): Onychomykose: Epidemiologie, Pathogenese, Klinik, Mikrobiologie und Therapie. Dtsch. Ärztebl. 93: A-2027–2032.

    Google Scholar 

  • Akpan A., Morgan R. (2002): Oral candidiasis. Postgrad. Med. J. 78: 455–459.

    Article  PubMed  CAS  Google Scholar 

  • Albougy H.A., Naidoo S. (2002): A systematic review of the management of oral candidiasis associated with HIV/AIDS. J. South African Dent. Ass. 57: 457–466.

    CAS  Google Scholar 

  • Amichai B., Grunwald M.H. (1998): Adverse drug reactions of the new oral antifungal agents — terbinafine, fluconazole, and itraconazole. Int. J. Dermatol. 37: 410–415.

    Article  PubMed  CAS  Google Scholar 

  • Area E., Tastan H. B., Akar A., Kurumlu Z., Gur A.R. (2002): An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J. Dermatol. Treat. 13: 3–9.

    Article  Google Scholar 

  • Ariyaratnam S., Thakker N.S., Sloan P., Thornhill M.H. (1997): Potentiation of warfarin anticoagulant activity by miconazole oral gel. Brit. Med. J. 314: 349.

    Article  PubMed  CAS  Google Scholar 

  • Bell-Syer S.E.M., Hart R., Crawford E, Torgerson DJ., Tyrell W., Russell I. (2003): Oral treatments for fungal infections of the skin of the foot (Cochrane Review). In: The Cochrane Library, Issue 2 2003. Oxford: Update Software.

    Google Scholar 

  • Bennett M.L., Fleischer A.B., Loveless J.W., Feldman S.R. (2000): Oral griseofulvin remains the treatment of choice for tinea capitis in children. Ped. Dermatol. 17: 304–309.

    Article  CAS  Google Scholar 

  • Blaschek-Hellmessen R., Buchmann H., Schwarze R. (1996): Einfluß oral verabreichter Polyenantibiotika auf die Hefepilzbesiedlung des Darmtraktes: Möglichkeiten und Grenzen. Mycoses 39(Suppl. 1): 33–39.

    Article  Google Scholar 

  • Casciano J., Amaya K., Doyle J., Arikian S., Shear N., Haspel M., Kahler K. (2003): Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag. Care 12: 47–54.

    PubMed  Google Scholar 

  • Chu A.C. (1984): Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. Dermatologica 169 (Suppl. 1): 81–86.

    Article  PubMed  Google Scholar 

  • Crawford F., Hart R., Bell-Syer S.E.M., Torgerson DJ., Young P., Rüssel I. (2001): Athlete’s foot and fungally infected toenails. Br. Med. J. 322: 288–289.

    Article  CAS  Google Scholar 

  • Crawford E, Young P., Godfrey C, Bell-Syer S.E.M., Hart R., Brunt E., Rüssel I. (2002): Oral treatments for toenail onychomycosis. Arch. Dermatol. 138: 811–816.

    Article  PubMed  CAS  Google Scholar 

  • Crawford E, Hart R., Bell-Syer S., Torgerson D., Young P., Russell I. (2003): Topical treatments for fungal infections of the skin and nails of the foot (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.

    Google Scholar 

  • Darkes M.J.M., Scott L.J., Goa K.L. (2003): Terbinafine. A review of its use in onychomycosis in adults. Am. J. Clin. Dermatol. 4: 39–65.

    Article  PubMed  Google Scholar 

  • Devaraj A., O’Beirne J.P., Veasey R., Dunk A. (2002): Interaction between warfarin and topical miconazole cream. Br. Med. J. 325: 77.

    Article  CAS  Google Scholar 

  • Dinnendahl V., Fricke U. (Hrsg.) (2003): Arzneistoff-Profile. Basisinformation über arzneiliche Wirkstoffe. Stammlieferung 1982 mit 1. bis 18. Ergänzungslieferung 2003, Govi-Verlag, Eschborn.

    Google Scholar 

  • Drake L., Babel D., Stewart D.M., Rich P., Ling M.R., Breneman D. et al. (1998): Onceweekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J. Am. Acad. Dermatol. 38: 87–94.

    Article  Google Scholar 

  • Ellis D. (2002): Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49(Suppl.Sl):7–10.

    Article  PubMed  CAS  Google Scholar 

  • Evans E.G.V., Sigurgeirsson B. for the LION study group (1999): Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Brit. Med. J. 318:1031–1035.

    Article  PubMed  CAS  Google Scholar 

  • Friedlander S.E, Suarez S. (1998): Pédiatrie antifungal therapy. Ped. Dermatol. 16: 527–537.

    CAS  Google Scholar 

  • Friedlander S.E (2000): The optimal therapy for tinea capitis. Ped. Dermatol. 17: 325–326.

    Article  CAS  Google Scholar 

  • Goa K.L., Barradell L. B. (1995): Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50: 658–690.

    Article  PubMed  CAS  Google Scholar 

  • Grant S.M., Clissold S.P. (1989): Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344.

    Article  PubMed  CAS  Google Scholar 

  • Grant S.M., Clissold S.P. (1990): Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877–916.

    Article  PubMed  CAS  Google Scholar 

  • Grotzsche P.C., Johansen H.K. (2003): Nystatin prophylaxis and treatment in severely immunodepresses patients (Cochrane Review): In: The Cochrane Library, Issue 2 2003. Oxford: Update Software.

    Google Scholar 

  • Gupta A.K. (2002): Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J. Am. Podiatr. Med. Assoc. 92: 272–286.

    PubMed  Google Scholar 

  • Gupta A.K., Del Rosso J.Q. (2000): An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents.Int J. Dermatol. 39: 401–411.

    Article  PubMed  CAS  Google Scholar 

  • Gupta A.K., Sauder D.N., Shear N.H. (1994): Antifungal agents: An overview. Part I+II. J. Am. Acad. Dermatol. 30: 677–698 und 911-933.

    Article  PubMed  CAS  Google Scholar 

  • Gupta A.K., Gonder J.R., Shear N.H., Dilworth G.R. (1996): The development of green vision in association with terbinafine therapy. Arch. Dermatol. 132: 845–846.

    Article  PubMed  CAS  Google Scholar 

  • Gupta A.K., Einarson T.R., Summerbell R.C., Shear N.H. (1998): An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 55: 645–674.

    Article  PubMed  CAS  Google Scholar 

  • Gupta A.K., Shear N.H. (1999): The new oral antifungal agents for onychomycosis of the toenails. J. Eur. Acad. Dermatol. Venereol. 13: 1–13.

    Article  PubMed  CAS  Google Scholar 

  • Gupta A.K., Lynde C.W., Konnikov N. (2001a): Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 44:485–491.

    Article  PubMed  CAS  Google Scholar 

  • Gupta A.K., Lambert J., Revuz J., Shear N. (2001b): Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur. J. Dermatol. 11: 6–10.

    PubMed  CAS  Google Scholar 

  • Haria M., Bryson H.M. (1995): Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 49: 103–120.

    Article  PubMed  CAS  Google Scholar 

  • Haria M., Bryson H.M., Goa K.L. (1996): Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51: 585–620.

    Article  PubMed  CAS  Google Scholar 

  • Haugh M., Helou S., Boissel J.P., Cribier B.J. (2002): Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br. J. Dermatol. 147: 118–121.

    Article  PubMed  CAS  Google Scholar 

  • Higgins E.M., Fuller L.C., Smith C.H. (2000): Guidelines for the management of tinea capitis. Br. J. Dermatol. 143: 53–58.

    Article  PubMed  CAS  Google Scholar 

  • Hornstein O.P., Nürnberg E. (Hrsg.) (1985): Externe Therapie von Hautkrankheiten: Pharmazeutische und medizinische Praxis. Georg Thieme Verlag, Stuttgart, New York, pp. 304–315.

    Google Scholar 

  • Howard R.M., Frieden IJ. (1999): Dermatophyte infections in children. Adv. Pediatr. Infect. Dis. 14:73–107.

    PubMed  CAS  Google Scholar 

  • Katsambas A., Rigopoulos D., Antoniou C., Zachari A., Fragouli E., Stratigos J. (1996): Econazole 1% shampoo versus selenium in the treatment of tinea versicolor: A single-blind randomized clinical study. Int. J. Dermatol. 35: 667–668.

    Article  PubMed  CAS  Google Scholar 

  • Körting H.C. (1995): Dermatotherapie. Springer-Verlag, Berlin, Heidelberg, New York.

    Book  Google Scholar 

  • Lacour M., Zunder T., Huber R., Sander A., Daschner F., Frank U. (2002): The pathogenic significance of intestinal Candida colonization — A systematic review from an interdisciplinary and environmental medical point of view. Int. J. Hyg. Environ. Health 205: 257–268.

    Article  PubMed  Google Scholar 

  • Male O. (1981): Medizinische Mykologie für die Praxis. Georg Thieme Verlag, Stuttgart, New York.

    Google Scholar 

  • McClellan K.J., Wiseman L.R., Markham A. (1999): Terbinafine. An update of its use in superficial mycoses. Drugs 58: 179–202.

    Article  PubMed  CAS  Google Scholar 

  • Merk H.E (1993): Antimykotika. Teil I und IL Hautarzt 44: 191–199 und 257-267.

    CAS  Google Scholar 

  • Niewerth M., Körting H.C. (1999): Management of onychomycoses. Drugs 58: 283–296.

    Article  PubMed  CAS  Google Scholar 

  • Niewerth M., Körting H.C. (2000): The use of systemic antimycotics in dermatotherapy. Eur. J. Dermatol. 10: 155–160.

    PubMed  CAS  Google Scholar 

  • Patton L.L., Bonito A.J., Shugars D.A. (2001): A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg. Oral Med. Pathol. Oral Radiol. Endod. 92: 170–179.

    Article  CAS  Google Scholar 

  • Pierard G.E., Arrese J.E., Pierard-Franchimont C. (1996): Treatment and prophylaxis of tinea infections. Drugs 52: 209–224.

    Article  PubMed  CAS  Google Scholar 

  • Powderly W.G., Mayer K.H., Perfect J.R. (1999): Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res. Hum. Retroviruses 15: 1405–1412.

    Article  PubMed  CAS  Google Scholar 

  • Quintanar-Guerrero D., Ganem-Quintanar A., Tapia-Olguin P., Kaliar Y.N., Buri P. (1998): The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev. Ind. Pharm. 24: 685–690.

    Article  PubMed  CAS  Google Scholar 

  • Ring J., Fröhlich H.H. (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl. Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, pp. 133–136 und 211-213.

    Book  Google Scholar 

  • Schäfer-Körting M., Blechschmidt J. Körting H.C. (1996): Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses 39: 329–339.

    Article  PubMed  Google Scholar 

  • Scher R.K., Breneman D., Rich P., Savin R.C. Feingold D.S., Konnikov N. et al. (1998): Once-weekly fluconazole (150,300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J. Am. Acad. Dermatol. 38: 77–86.

    Article  Google Scholar 

  • Scholz H., Schwabe U. (Hrsg.) (2000): Taschenbuch der Arzneibehandlung. Angewandte Pharmakologie, 12. Aufl. Urban& Fischer München, Jena.

    Google Scholar 

  • Sigurgeirsson B., Olafsson J.H., Steinsson J. B., Paul C, Billstein S., Evans E.G.V. (2002): Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. Arch. Dermatol. 138: 353–357.

    Article  PubMed  CAS  Google Scholar 

  • Silingardi M., Ghirarduzzi A., Tincani E., Lorio A., Iori I. (2000): Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb. Haemost. 83: 794–795.

    PubMed  CAS  Google Scholar 

  • Simon C, Stille W. (2000): Antibiotika-Therapie in Klinik und Praxis, 10. Auflage. Schattauer, Stuttgart-New York, S. 330–336.

    Google Scholar 

  • Steigleder G.K. (1993): Therapie der Hautkrankheiten, 4. Aufl. Georg Thieme Verlag, Stuttgart, New York.

    Google Scholar 

  • Thirion DJ., Zanetti L.A. (2000): Potentiation of warfarin’s hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy 20: 98–99.

    Article  PubMed  CAS  Google Scholar 

  • Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. (2000): Effects of the antifungal agents on oxidative drug metabolism. Clin. Pharmacokinet. 38: 111–180.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Uwe Fricke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universitat Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fricke, U. (2004). Antimykotika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18512-0_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40188-9

  • Online ISBN: 978-3-642-18512-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation